Lorenzo Tallarigo Purchases 75,417 Shares of Oxford BioMedica plc (OXB) Stock
Oxford BioMedica plc (LON:OXB) insider Lorenzo Tallarigo bought 75,417 shares of the stock in a transaction that occurred on Friday, November 25th. The shares were bought at an average cost of GBX 4 ($0.05) per share, with a total value of £3,016.68 ($3,742.31).
Lorenzo Tallarigo also recently made the following trade(s):
- On Tuesday, October 25th, Lorenzo Tallarigo purchased 77,864 shares of Oxford BioMedica plc stock. The shares were acquired at an average cost of GBX 3 ($0.04) per share, with a total value of £2,335.92 ($2,897.80).
- On Monday, September 26th, Lorenzo Tallarigo purchased 79,988 shares of Oxford BioMedica plc stock. The shares were acquired at an average cost of GBX 3 ($0.04) per share, with a total value of £2,399.64 ($2,976.85).
Shares of Oxford BioMedica plc (LON:OXB) opened at 3.60 on Wednesday. The stock’s market capitalization is GBX 111.17 billion. The stock has a 50 day moving average price of GBX 3.46 and a 200 day moving average price of GBX 4.15. Oxford BioMedica plc has a 12-month low of GBX 2.98 and a 12-month high of GBX 8.45.
OXB has been the subject of a number of recent analyst reports. Jefferies Group initiated coverage on Oxford BioMedica plc in a report on Friday, October 21st. They set a “buy” rating and a GBX 8 ($0.10) price target for the company. N+1 Singer reaffirmed a “hold” rating and set a GBX 3.30 ($0.04) price target on shares of Oxford BioMedica plc in a report on Tuesday.
Oxford BioMedica plc Company Profile
Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company’s segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners.
Receive News & Stock Ratings for Oxford BioMedica plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica plc and related stocks with our FREE daily email newsletter.